logo
Meta Platforms Stock: Buy, Hold, or Sell?

Meta Platforms Stock: Buy, Hold, or Sell?

Globe and Mail29-03-2025
Meta Platforms ' (NASDAQ: META) shares have been through a remarkable ride over the last two years after hitting a low in 2022.
Thanks to its successful turnaround efforts, the social media giant has delivered another year of solid performance, sustaining the momentum achieved in 2023. Unsurprisingly, its solid performance drove the stock price to a new all-time high in 2024.
But investors might now be facing other dilemmas. Is now the time to buy the stock? Or, for those who already own the stock, is now a good time to sell?
Family of Apps continues to deliver on its promises
Last year marked another period of solid performance by Meta's core advertising business. Revenue grew by 22%, while income from operations jumped 39%.
Such a performance was remarkable, considering that Meta was already generating $133 billion in revenue and $63 billion in operating profit in 2023. It's even more impressive if we consider that the tech giant faced huge challenges with stagnant revenue and falling profits in 2022. In other words, it went from being a problem child to reaching new heights in both revenue and profits.
Meta's solid comeback reflects the strength of its business model. With 3.35 billion daily active users (DAU), Meta is the biggest social media networking company -- it owns Facebook, Messenger, Instagram, and WhatsApp. Better still, this number continues to grow -- it expanded by 5% year over year in the latest quarter.
As owner of the largest social network, Meta offers a compelling service for users to stay connected with friends and family. In return, users remain highly engaged with its services, enabling the tech giant to grow its advertising business over time. In 2024, ad impressions and ad pricing rose by 11% and 10%, respectively, underscoring the attractiveness of this business.
Meta has continuously worked on its product offerings to delight its users, the latest being incorporating artificial intelligence (AI) into its apps. For instance, the company improves its content feed to users by employing the latest AI technology, making sure users get the right content to keep them engaged. It also expects that Meta AI, a highly intelligent and personalized assistant, will reach its users in the near future.
Assuming that it delivers on its AI promises, Meta is well-positioned to keep its user base even more engaged in the near future. That, in turn, should keep its advertising business robust (and growing) for a while.
Reality Labs remains deeply in the red
While Meta's core business continues to fire on all cylinders, its investment in the metaverse business remains a question mark.
In 2024, this business continued to bleed cash as its operating losses grew from $16 billion to $18 billion. Despite its growing losses, revenue remained almost unchanged at $2 billion. This poor performance suggests that the tech company faces challenges in monetizing this business.
On one hand, the company remains optimistic about the future of this industry, and for good reason. According to Statista, the metaverse market size could reach $508 billion by 2030. It makes sense for Meta to invest early on to position itself as a potential winner. Besides, the metaverse complements the company's existing social networking business, especially if users choose to engage with their friends in the metaverse environment in the future.
The downside is that there is no certainty as to when the metaverse will reach mainstream or how big the addressable market size will eventually be. After all, the half-trillion-dollar market size is just a prediction. If the market opportunity fails to materialize, the tens of billions of dollars invested (yearly) would be value-destroying.
An overview of Meta's stock valuation
Another aspect that investors should consider before making any move on Meta's stock is its valuation. As of this writing, the stock has a price-to-earnings (P/E) ratio of 28, which is on the higher end of its range in the last five years.
While it's not unreasonable for the stock to trade at a rich multiple, considering the quality of the advertising business, investors are not getting any bargains in buying the stock at its current valuation.
What it all means for investors
Meta ended 2024 with a bang as its advertising business returned to its historical growth trajectory. As the company monetizes its app family, it could sustain growth in the coming quarters.
The downside is that its investment in Reality Labs remains deeply in the red, consuming enormous profits from its advertising business. Besides, Meta's stock doesn't trade at a bargain price, so investors don't get much of a margin of safety.
While Meta stock is not a sell, it's hard to advocate buying it right now. It's best for those who already own the stock to hold on to it, while potential investors should wait for a better entry point.
Don't miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $284,402!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $41,312!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $503,617!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of March 24, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe and Mail

time13 minutes ago

  • Globe and Mail

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia's common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.69 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's inducement award program and a stock option agreement covering the grant. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at which does not form a part of this release.

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe and Mail

time13 minutes ago

  • Globe and Mail

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact:

AXT (AXTI) Q2 Revenue Drops 36%
AXT (AXTI) Q2 Revenue Drops 36%

Globe and Mail

timean hour ago

  • Globe and Mail

AXT (AXTI) Q2 Revenue Drops 36%

Key Points Non-GAAP loss per share widened to ($0.15) versus estimates of ($0.13), reflecting soft demand and margin compression. Positive movement seen in indium phosphide (InP) substrate shipments linked to early artificial intelligence demand, but not enough to offset broader weakness. These 10 stocks could mint the next wave of millionaires › AXT (NASDAQ:AXTI), a specialty materials producer known for high-performance semiconductor substrates, reported second-quarter 2025 earnings on July 31, 2025. The headline news from the release was a sharper-than-expected revenue decline, as GAAP revenue was $18.0 million, missing the analysts' estimate of $19.78 million by $1.78 million, or 9.0%, with non-GAAP earnings falling short of market estimates amid ongoing pressure from regulatory delays and a slow demand environment in China. GAAP revenue was $18.0 million, missing the $19.8 million GAAP analyst estimate, while non-GAAP loss per share was ($0.15), instead of the expected ($0.13) (non-GAAP). The quarter's overall performance showed persistent challenges, with some improvement in gross margin from the prior period but continued losses and steep year-over-year declines (GAAP gross margin 8.0%, up from (6.4)% in Q1 2025 and down from 27.4% in Q2 2024; non-GAAP gross margin 8.2%, up from (6.1)% in Q1 2025 and down from 27.6% in Q2 2024). Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) ($0.15) ($0.13) ($0.02) (650.0%) Revenue (GAAP) $18.0 million N/A $27.9 million (35.5%) Gross Margin (Non-GAAP) 8.2% 27.6% (19.4 pp) Net Loss (Non-GAAP) ($6.4 million) ($0.8 million) 700.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report. About AXT: Business Overview and Strategic Focus AXT manufactures compound semiconductor substrates such as gallium arsenide (GaAs), indium phosphide (InP), and germanium (Ge). These substrates serve as foundational materials in products for the data center, wireless, 5G, LED, and automotive sectors. Its products are used in applications such as artificial intelligence, optical networking, and advanced sensing. The company has recently focused on strengthening its position in high-growth areas like AI-driven optical interconnects, where efficient data processing and transmission are key. Maintaining a vertically integrated supply chain and pushing for advanced substrate quality have also become central, as has managing exposure to geopolitical and regulatory headwinds in China. Successfully expanding manufacturing scale and securing export permits remain crucial factors going forward. Quarter in Review: Revenue Declines, Margin Recovery, and Emerging Demand Trends This was also a sequential decline from the previous period's $19.4 million GAAP revenue. GAAP revenue came in $1.8 million below analyst expectations. Management attributed this shortfall mostly to longer processing times for gallium arsenide export permits and a sluggish demand environment in China. Raw material sales also faced pressure from these trends. While non-GAAP gross margin improved from negative territory in the previous quarter to 8.2%, this still lagged well behind last year's non-GAAP gross margin of 27.6%. The partial margin recovery reflects some success in process and operational improvements, though it remains well below optimal levels due to lower sales volume and ongoing cost challenges. One positive development for the business was the growth in substrate shipments for AI-related applications. Indium phosphide (InP) substrates, essential for high-speed optical data transmission in data centers and advanced computing, saw increased demand in China. Management pointed to its first successful exports of InP substrates outside China following new export permit approvals in June. Even so, these gains did not offset widespread softness in other end markets. Geopolitical and regulatory obstacles, especially related to China, were major themes this quarter. The delay and complexity of export permit processes weighed on expected sales, as did continued uncertainties in the broader Chinese economy. The ongoing regulatory review for the company's STAR Market IPO—the planned public offering of its subsidiary Tongmei in China—remains unresolved. Business Drivers, Product Lines, and Key Risks AXT's performance relies on the demand for high-quality substrates in data-intensive and high-speed applications. Its key product types—gallium arsenide, indium phosphide, and germanium substrates—are used for things like 5G base stations, lasers for data centers, and high-efficiency solar cells. Success in offering superior technical specifications, like low etch pit density (a measure of crystal quality), helps the company meet evolving customer requirements for next-generation devices. The company operates a vertically integrated supply chain, with partial ownership of raw material companies in China. This setup should, in theory, help with pricing, supply reliability, and cost control. However, increased operational costs and limited flexibility amid falling revenue have highlighted the balance between integration benefits and the risks of heavy concentration in China. Regulatory and trade restrictions remain a material risk, as delays in exporting key substrate products impact revenue and growth plans. No explicit dividend was declared this quarter, aligning with the company's current practice. Looking Ahead: Guidance and Investor Focus Instead, it underscored a focus on improving operational efficiency, supporting next-generation technology needs, and working to expand access to markets outside China as new export permits are granted. There are some early signs of demand recovery tied to AI-driven uses for InP substrates, but these remain small relative to the company's overall scale and current headwinds. Investors should watch for developments around external orders for high-speed substrates, trends in inventory and cash flow, and any updates on the STAR Market IPO for Tongmei. The company's ability to access capital and scale production as demand recovers will be critical. AXT does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of July 29, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store